123 related articles for article (PubMed ID: 19197461)
1. [Oncogenic osteomalacia: localization of underlying peripheral tumor with 99mTc-sestamibi scintigraphy].
Biagini GL; Coutinho PR; Jonasson TH; Ueda CE; Gama RR
Arq Bras Endocrinol Metabol; 2008 Dec; 52(9):1505-9. PubMed ID: 19197461
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of 201Tl and 99mTc MIBI scintigraphy in a case of oncogenic osteomalacia.
Kimizuka T; Ozaki Y; Sumi Y
Ann Nucl Med; 2004 Feb; 18(1):63-7. PubMed ID: 15072186
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic osteomalacia: localization of underlying peripheral mesenchymal tumors with use of Tc 99m sestamibi scintigraphy.
Hodgson SF; Clarke BL; Tebben PJ; Mullan BP; Cooney WP; Shives TC
Endocr Pract; 2006; 12(1):35-42. PubMed ID: 16524861
[TBL] [Abstract][Full Text] [Related]
4. Occult phosphaturic mesenchymal tumor detected by Tc-99m sestamibi scan.
Siegel HJ; Rock MG
Clin Nucl Med; 2002 Aug; 27(8):608-9. PubMed ID: 12170016
[No Abstract] [Full Text] [Related]
5. Coexisting hyperparathyroidism and oncogenic osteomalacia: Sestamibi and somatostatin receptor scintigraphy.
Nguyen BD
Clin Nucl Med; 2006 Oct; 31(10):648-51. PubMed ID: 16985379
[No Abstract] [Full Text] [Related]
6. Concordance between whole-body scintigraphy 111In-octreotide and 99mTc-sestamibi uptake in the detection of four tumor-induced osteomalacia cases.
Ferraz MP; Watanabe T; Sado HN; Ono CR; Buchpiguel CA; Correa PH; Martin RM
J Clin Endocrinol Metab; 2014 Mar; 99(3):699-700. PubMed ID: 24423352
[No Abstract] [Full Text] [Related]
7. Treatment and outcomes of tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors: retrospective review of 12 patients.
Zuo QY; Wang H; Li W; Niu XH; Huang YH; Chen J; You YH; Liu BY; Cui AM; Deng W
BMC Musculoskelet Disord; 2017 Sep; 18(1):403. PubMed ID: 28934935
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic osteomalacia: exact tumor localization by co-registration of positron emission and computed tomography.
Hesse E; Moessinger E; Rosenthal H; Laenger F; Brabant G; Petrich T; Gratz KF; Bastian L
J Bone Miner Res; 2007 Jan; 22(1):158-62. PubMed ID: 17014386
[TBL] [Abstract][Full Text] [Related]
9. Effective detection of the tumors causing osteomalacia using [Tc-99m]-HYNIC-octreotide (99mTc-HYNIC-TOC) whole body scan.
Jing H; Li F; Zhuang H; Wang Z; Tian J; Xing X; Jin J; Zhong D; Zhang J
Eur J Radiol; 2013 Nov; 82(11):2028-34. PubMed ID: 23721625
[TBL] [Abstract][Full Text] [Related]
10. Tumor-induced hypophosphatemic osteomalacia associated with tertiary hyperparathyroidism: a case report.
Tartaglia F; Minisola S; Sgueglia M; Blasi S; Brunelli D; Degli Effetti E; Maturo A; Cola A; Custureri F; Campana FP
G Chir; 2006; 27(1-2):9-13. PubMed ID: 16608626
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer-induced oncogenic hypophosphatemic osteomalacia.
Nakahama H; Nakanishi T; Uno H; Takaoka T; Taji N; Uyama O; Kitada O; Sugita M; Miyauchi A; Sugishita T
Urol Int; 1995; 55(1):38-40. PubMed ID: 7571183
[TBL] [Abstract][Full Text] [Related]
12. A case of oncogenic osteomalacia detected by 111In-pentetreotide total body scan.
Casari S; Rossi V; Varenna M; Gasparini M; Parafioriti A; Failoni S; Sinigaglia L
Clin Exp Rheumatol; 2003; 21(4):493-6. PubMed ID: 12942704
[TBL] [Abstract][Full Text] [Related]
13. Tumor-induced osteomalacia: successful treatment by radio-guided tumor surgery.
Harbeck B; Schöcklmann H; Seekamp A; Czech N; Mönig H
J Clin Rheumatol; 2009 Feb; 15(1):31-4. PubMed ID: 19125132
[TBL] [Abstract][Full Text] [Related]
14. A rare case of multiple phosphaturic mesenchymal tumors along a tendon sheath inducing osteomalacia.
Arai R; Onodera T; Terkawi MA; Mitsuhashi T; Kondo E; Iwasaki N
BMC Musculoskelet Disord; 2017 Feb; 18(1):79. PubMed ID: 28193220
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of tumor-induced osteomalacia with 111In-pentetreotide scintigraphy.
Palot Manzil FF; Bhambhvani PG; O'Malley JP
J Nucl Med Technol; 2013 Dec; 41(4):299-301. PubMed ID: 24159011
[TBL] [Abstract][Full Text] [Related]
16. [Detection of the primary tumor site in tumor-induced osteomalacia by indium-111 octreotide scintigraphy: a case report].
Takahashi M; Toru S; Ota K; Izumiyama H; Yokota T; Mizusawa H
Rinsho Shinkeigaku; 2008 Feb; 48(2):120-4. PubMed ID: 18326305
[TBL] [Abstract][Full Text] [Related]
17. Hypophosphaturic mesenchymal tumor of the ethmoid associated with oncogenic osteomalacia.
Ungari C; Rocchi G; Rinna C; Agrillo A; Lattanzi A; Pagnoni M
J Craniofac Surg; 2004 May; 15(3):523-7. PubMed ID: 15111823
[TBL] [Abstract][Full Text] [Related]
18. Technetium-99m sestamibi leg scintigraphy for non-invasive assessment of propionyl-L-carnitine induced changes in skeletal muscle metabolism.
Cittanti C; Colamussi P; Giganti M; Orlandi C; Uccelli L; Manfrini S; Azzena G; Piffanelli A
Eur J Nucl Med; 1997 Jul; 24(7):762-6. PubMed ID: 9211762
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic osteomalacia: two case reports with surprisingly different outcomes.
Seijas R; Ares O; Sierra J; Pérez-Dominguez M
Arch Orthop Trauma Surg; 2009 Apr; 129(4):533-9. PubMed ID: 19125258
[TBL] [Abstract][Full Text] [Related]
20. 68Ga DOTA-TATE PET/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT/CT.
Breer S; Brunkhorst T; Beil FT; Peldschus K; Heiland M; Klutmann S; Barvencik F; Zustin J; Gratz KF; Amling M
Bone; 2014 Jul; 64():222-7. PubMed ID: 24769333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
